<DOC>
	<DOCNO>NCT00883909</DOCNO>
	<brief_summary>ARI103094 follow-up study adult male subject receive investigational product ( either dutasteride placebo ) REDUCE Study ( REduction DUasteride prostate Cancer Events ) , ARI40006 , A Randomized , Double-Blind , Placebo-Controlled , Parallel Group Study Efficacy Safety Dutasteride 0.5mg Administered Orally Once Daily Four Years Reduce Risk Biopsy-Detectable Prostate Cancer . There 2 part REDUCE Follow-Up Study , Part A Part B : - REDUCE Follow-Up Study , Part A , 2 year observational study follow eligible subject 2 year completion 4 Contact REDUCE study . Eligible subject Part A , 2 Year Observational Study fall 3 group follow : ( 1 ) REDUCE subject complete treatment investigational product ( dutasteride placebo ) REDUCE 4 Year study visit [ Visit 10 ] , ( 2 ) REDUCE subject developed prostate cancer , withdraw investigational product participate Prostate Cancer follow-up REDUCE 4 Year study visit [ Visit 10P ] ( 3 ) REDUCE subject withdraw investigational product participate observational phone follow REDUCE 4 Year phone call withdraw IP ( expect Visit 10 ) . The objective observational study eligible REDUCE subject collect summarize data prostate cancer ( incidence newly diagnose prostate cancer change prostate cancer diagnose REDUCE study ) serious adverse event ( SAEs ) 2 year beyond prospectively plan 4 year double blind , placebo-controlled study , REDUCE . - REDUCE Follow-Up Study , Part B , collection cancer positive prostate biopsy tissue blocks/slides subject diagnosed prostate cancer REDUCE study .</brief_summary>
	<brief_title>ARI103094-Follow-Up Study REDUCE Study Subjects</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>PART A Any subject participate REDUCE Study meet one follow eligibility criterion eligible Part A , 2 Year Observational FollowUp Study : Completed 4 year Investigational Product REDUCE 4 Year study visit ( Visit 10 ) OR Was diagnose prostate cancer REDUCE study , discontinue Investigational Product ( IP ) participate REDUCE Prostate Cancer FollowUp visit 4 Year study visit ( Visit 10P ) OR Withdrew REDUCE study visit participation IP ( reason ) participate REDUCE FollowUp phone call every 6 month 4 Year phone call PART A Subjects meeting follow criterion must enrol Part A study Inability/unwillingness participate FollowUp Study phone call . PART B Subjects eligible enrolment Part B study must meet following criterion : Any subject diagnose prostate cancer base prostate biopsy participation REDUCE Study , regardless REDUCE study participation end . PART B The exclusion criterion applies Part A , 2 year Observational FollowUp Study . There exclusion criterion Part B , Prostate Biopsy Tissue Study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
</DOC>